These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22901971)

  • 1. Effect of gender, caregiver, on cholesterol control and statin use for secondary prevention among hospitalized patients with coronary heart disease.
    Hammond G; Mochari-Greenberger H; Liao M; Mosca L
    Am J Cardiol; 2012 Dec; 110(11):1613-8. PubMed ID: 22901971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients.
    Munkhaugen J; Sverre E; Otterstad JE; Peersen K; Gjertsen E; Perk J; Gullestad L; Moum T; Dammen T; Husebye E
    Eur J Prev Cardiol; 2017 Jun; 24(9):981-989. PubMed ID: 28196429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
    Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesterol end points predict outcome in patients with coronary disease: quality improvement metrics from the enhancing secondary prevention in coronary artery disease (ESP-CAD) trial.
    McAlister FA; Majumdar SR; Lin M; Bakal J; Fradette M; Anderson T
    Can J Cardiol; 2014 Dec; 30(12):1627-32. PubMed ID: 25307535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sigmoidal maximal effect modeling of low-density lipoprotein cholesterol concentration and annual incidence of coronary heart disease events in secondary prevention trials.
    Charland SL; Stanek EJ
    Pharmacotherapy; 2014 May; 34(5):452-63. PubMed ID: 24877185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
    Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
    Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender differences in achieving optimal lipid goals in patients with coronary artery disease.
    Victor BM; Teal V; Ahedor L; Karalis DG
    Am J Cardiol; 2014 May; 113(10):1611-5. PubMed ID: 24698458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis.
    Jones PH; Nair R; Thakker KM
    J Am Heart Assoc; 2012 Dec; 1(6):e001800. PubMed ID: 23316314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between persistence with statin therapy and reduction in low-density lipoprotein cholesterol level: analysis of real-life data from community settings.
    Shalev V; Goldshtein I; Halpern Y; Chodick G
    Pharmacotherapy; 2014 Jan; 34(1):1-8. PubMed ID: 23836549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin Intensity and Clinical Outcome in Patients with Stable Coronary Artery Disease and Very Low LDL-Cholesterol.
    Lee SY; Oh SJ; Kim EJ; Oum CY; Park SH; Oh J; Kim JS; Kim BK; Park S; Chang HJ; Hong GR; Ko YG; Kang SM; Choi D; Ha JW; Hong MK; Jang Y; Chung N; Lee SH
    PLoS One; 2016; 11(11):e0166246. PubMed ID: 27824924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.
    Reiner Ž; De Backer G; Fras Z; Kotseva K; Tokgözoglu L; Wood D; De Bacquer D;
    Atherosclerosis; 2016 Mar; 246():243-50. PubMed ID: 26812002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.
    Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
    Am J Cardiol; 2007 Nov; 100(10):1499-501. PubMed ID: 17996508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effects of two low-density lipoprotein cholesterol goals for secondary prevention after acute myocardial infarction in real-world practice: ≥ 50% reduction from baseline versus <70 mg/dL.
    Cho KH; Jeong MH; Park KW; Kim HS; Lee SR; Chae JK; Hong YJ; Kim JH; Ahn Y; Cho JG; Park JC;
    Int J Cardiol; 2015; 187():478-85. PubMed ID: 25846658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
    Nicholls SJ; Tuzcu EM; Sipahi I; Grasso AW; Schoenhagen P; Hu T; Wolski K; Crowe T; Desai MY; Hazen SL; Kapadia SR; Nissen SE
    JAMA; 2007 Feb; 297(5):499-508. PubMed ID: 17284700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporal Trends in Statin Prescriptions and Residual Cholesterol Risk in Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
    Guedeney P; Claessen BE; Baber U; Camaj A; Sorrentino S; Aquino M; Blum M; Chandiramani R; Goel R; Elsayed S; Kovacic JC; Sweeny J; Barman N; Moreno P; Dangas GD; Kini A; Sharma S; Mehran R
    Am J Cardiol; 2019 Jun; 123(11):1788-1795. PubMed ID: 30955866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants for achieving the LDL-C target of lipid control for secondary prevention of cardiovascular events in Taiwan.
    Ho LT; Yin WH; Chuang SY; Tseng WK; Wu YW; Hsieh IC; Lin TH; Li YH; Huang LC; Wang KY; Ueng KC; Fang CC; Pan WH; Yeh HI; Wu CC; Chen JW;
    PLoS One; 2015; 10(3):e0116513. PubMed ID: 25756522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin prescription strategies and atherogenic cholesterol goals attainment in Lebanese coronary artery disease patients.
    Lama S; Souraya D; Youssef F
    Int J Clin Pharm; 2017 Aug; 39(4):919-926. PubMed ID: 28523462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.